 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Review, Journal: Novel drug candidates against antibiotic-resistant microorganisms: A review. (Pubmed Central) - Jan 18, 2024
In addition to these identified drug candidates, continued in vitro and in vivo studies are required to investigate small molecules with potential antibacterial effects screened by computational receptor docking. As drug discovery progresses, preclinical and clinical studies should also be extensively conducted on the currently available therapeutic agents to unravel their potential antibacterial effect and spectrum of activity, as well as safety and efficacy profiles.
- | GT-1 / Geom Therap
Journal: Antibacterial Activity of LCB10-0200 against Klebsiella pneumoniae. (Pubmed Central) - Oct 25, 2021
LCB10-0200 showed more potent in vivo activity than ceftazidime in the three in vivo models against the drug-susceptible and drug-resistant K. pneumoniae strains. Taken together, these results show that LCB10-0200 is a potential antibacterial agent to treat infection caused by K. pneumoniae.
- | GT-1 / Geom Therap
Preclinical, Journal: In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa Strains at a Tertiary Hospital in Korea. (Pubmed Central) - May 1, 2021
LCB10-0200 alone exhibited strong activity against selected strains. The addition of AVI significantly increased LCB10-0200 activity against carbapenem-resistant E. coli, K. pneumoniae.
- | GT-1 / Geom Therap, GT-055 / Geom Therap
Preclinical, Journal: In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains. (Pubmed Central) - May 24, 2020
GT-1 demonstrated potent in vitro activity against clinical panel strains of E. coli, K. pneumoniae and Acinetobacter spp. GT-055 enhanced the in vitro activity of GT-1 against many GT-1-resistant strains.
- GT-1 / Geom Therap, GT-055 / Geom Therap
Pharmacokinetics-pharmacodynamics of the novel beta-lactamase inhibitor GT-055 in combination with the siderophore cephalosporin GT-1 (Arena 2) - Apr 5, 2019 - Abstract #ECCMID2019ECCMID_4424;
When GT-055 is paired with the novel siderophore cephalosporin, GT-1 (formerly LCB10-0200), the BLI has been shown to improve the in vitro activity up to 8-fold against a variety of Gram-negative organisms including Enterobacteriaceae. Results of GT-1 + GT-055 in vitro studies provided insight about the activity of the inhibitor when utilized in combination with GT-1 and will serve to guide future studies.